Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Mentioned
Transcript
Transcript preview
Preview only
The large part of the industry makes medicines is this very empirically driven process. Where things really fail is in the clinic because we never could see the problems until we get to the point where we put these drugs in patients and we say, Oh no, like, there's toxicity that we didn't account for. And so the really big opportunity is to have much more of that understanding before you go into patients. How can we bring all of that drug discovery work onto a computer? So how can we get out of the real world? I'd be really disappointed if we fast forward even five years' time. Like, the predi
Do you have a prediction on when you think, for example, eighty percent of human cancers will be treatable? Today, know priors were joined by Max Jadberg. Max is the president and part of the founding team of Isomorphic Labs. Isomorphic is backed by Alphabet and a variety of other investors, and its goal is to solve all disease, which is very exciting as a topic. We're going to talk a little bit about the role of AI in the future of biopharma, human health, longevity. And Max, of course, has a background in machine learning. He has a PhD in the topic working on machine vision. Eventually sold
No. It's such a pleasure to be here.
Thank you. Isomorphic, I think, is is one of the more fascinating companies right now that's happening in technology in general. Alphabet is a major shareholder and sort of sponsor. Demis, who pioneered a lot of models at DeepMind and other places, which I believe you sold the company to before, you know, really helped with the inception and setup and now running of the company. And you folks are tackling one of the biggest problems that's left for humanity to tackle, which is human health. Could you tell me a bit about how you came to work on this company, and what was the motive force to sta
I was part of the founding team of Isomorphic Labs. I was at DeepMind for a long time beforehand. You know, personally, I was working on early days of generative models, language models, deep reinforcement learning, all of the big, you know, game playing challenge problems. Those were my jam. My AlphaGo, AlphaStar. And it got to the point where, you know, we were we were going after these, like, know, quote unquote impossible problems at that point in time. You know, this is probably twenty eighteen, nineteen, that's
sort It's like gameplay and can AI beat video games? Exactly.
You know, at that point in time, you know, we were still trying to prove to the world that AI was even a thing. Right? Mhmm. And so we were going after these impossible problems, and I could see, you know, firsthand, like, how to... Like, just systematically how to solve these. Mhmm. And it got to the point for me personally where it's like, okay. Sure. We're not at AGI yet, but we clearly have this amazing, you know, set of technologies, you know, in deep learning and reinforcement learning. And, you know, what are the problems we really need to be focusing this stuff on? And I was, you know,
Oh, amazing. Yeah. Your background really started off more on the deep learning side and AI modeling side, and I believe you sold the company to DeepMind in... Was it 2014?
Yeah. That's right.
Keep exploring with a free account.
A free account preserves the short preview. Upgrade to Pro for the full transcript and episode chat.